Sponsors for 2010

The ERBI conference could not take place without its sponsors - their support helps drive the service we provide through the event and we extend our thanks to them.

East of England Development Agency Gold Sponsor

EEDA has a clear mission – to improve the economy of the East of England, so whether it’s helping businesses through the recession, supporting people to be the best they can or breathing new life into places, everything we do comes back to our mission.

We do this by:

• Supporting businesses through the recession and beyond
• Supporting people to retrain, develop their skills and access jobs
• Working with local authorities and others to transform their local economies

We commission delivery at the 'right' level to meet demands, whether that is local, sub-regional or regional to provide the maximum return on investment. We believe in doing more for less; working with local authorities to help localities achieve their ambitions; and working in partnership with organisation like ERBI to make sure we have the greatest possible impact on businesses, people and places.

Website: www.eeda.org.uk

Merck & Co., Inc. Gold Sponsor

Merck & Co., Inc., Whitehouse Station, NJ, USA, is a global research-driven pharmaceutical company dedicated to putting patients first. Merck discovers, develops, manufactures, and markets vaccines and medicines in over 20 therapeutic categories directly and through its joint ventures. Our mission is to provide society with superior products and services by developing innovations and solutions that improve the quality of life.

At Merck, our strategy for growth is based on breakthrough research — both internal and external through partnerships — and demonstrating the value of our medicines to patients, payers, and providers. Worldwide sales in 2008 were $23.9 billion and Merck continues to invest heavily in research and development.

Merck's product line includes a broad portfolio of highly innovative prescription products in important therapeutic areas. Human health products include medicines to treat high blood pressure, elevated cholesterol levels, diabetes, cancer, osteoporosis, asthma, benign prostatic hypertrophy, arthritis, pain, migraine, glaucoma, infectious diseases (antibiotic, antifungal, and antiviral agents), and vaccines (to prevent childhood diseases, human papilloma virus, rotavirus, shingles, and hepatitis A and hepatitis B).

For further information, please visit our Web site at http://www.merck.com/licensing/

Abingworth Management LLP

Abingworth was founded in 1973 and is a key player among life science venture capital investors with offices in London, Cambridge (UK), Menlo Park, California and Boston, Massachusetts.

Specialising in life science and biomedical companies, Abingworth now has funds under management of over $1.25 billion and 32 staff including experienced professionals with operational, venture capital and public market investment expertise.

The company has backed more than 100 life science/medical firms, most of which have gone public or been acquired. Abingworth is a strongly science driven investment organisation that is prepared to take on substantial technical risk.

The management team has many years of operating experience and can actively assist scientific entrepreneurs in the development of their ideas into successful companies. Abingworth has the experience and resources to assist companies at any stage of development and take them beyond the IPO stage.

Website: www.abingworth.com
Email: info@abingworth.com

Chesterford Research Park

Chesterford Research Park offers state-of-the-art laboratory and office space specifically designed for research and as such attracts science and technology companies of all sizes. The innovative and sensitively developed 250 acre low density scheme and its location within the South Cambridgeshire Biotech cluster has established the Park as one of the UK’s leading R&D locations.

Our Focus

Chesterford Research Park provides the very best working environment for people and businesses from the biotech and R&D sector. Not only is it an established development, it is also a growing community with the Nucleus facility incorporating a restaurant, bar and lounge, health and fitness centre and state of the art meeting and conferencing facilities at its heart.

Now in its ninth year Chesterford Research Park is evolving into a unique scientific centre for the UK and has a firm vision for the future, encompassing further sympathetic expansion plans and the continued development of relationships within the current Park community.

Since its inception in 2000, joint developers of Chesterford Research Park, Aviva Investors and The Churchmanor Estates Company plc have not only retained and upgraded existing laboratory space but also created and let 250,000 sq ft of accommodation to major names including Pfizer, Illumina and Biofocus. They have also put into play the infrastructure, facilities, and management systems to be able to extend the development to approximately 600,000 sq ft.

The continuing development programme at the Park aims to provide secure, high quality, flexible accommodation for companies at all stages of their life cycle, with the Park team working closely with its occupiers, to continually satisfy their property requirements, as they change and grow.

For more information visit www.chesterfordresearchpark.co.uk

UK Trade & Investment (UKTI)

UK Trade & Investment is the government organisation that helps UK companies’ access new markets, and makes the right relationships internationally with a view to strengthening their businesses. The work of UK Trade & Investment includes:

• Trade support services for UK companies, provided nationally through a network of over 40 offices. Including researching markets and identifying hot leads, tailored to companies needs
• Inward investment development work within the UK, in collaboration with UK regional development agencies. Supporting quality foreign direct investment into the UK
• The trade and investment work of British Embassies worldwide. Specialists on the ground in-country to support UK companies

For more information about the work of UK Trade & Investment please visit www.uktradeinvest.gov.uk

To obtain details of your local UKTI Trade Team just call 0207 215 8000

EBD Group

EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group's partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.

EBD Group's conferences are run with the support of leading corporations and international trade associations, and include:

• BIO-Europe and BIO-Europe Spring®, Europe's largest life science partnering conferences, supported by the Biotechnology Industry Organization (BIO)
• ChinaBio® Partnering Forum, the largest and most productive partnering event in China
• BioPharm America™, the fastest growing partnering event in North America
• Biotech Showcase™, a unique forum in San Francisco for presenting to investors and business development executives
• EuroMedtech™, EBD Group's new partnering event for the innovative medical technology industry
• BioEquity Europe, the investor conference co-organized with BioCentury Publications and BIO

EBD Group's sophisticated web-based partnering service, partneringONE®, is used as the partnering engine at numerous third-party events around the world.

Outside of the conference format, EBD Group's consultants provide hands-on assistance for firms seeking to in- or out-license products and technologies. EBD Group has offices in the USA and Europe.

For more information visit: www.ebdgroup.com

 

Mintz Levin

Mintz Levin is a full-service law firm with 450 lawyers in the UK and US.

Working with biotech, pharmaceutical and medical device manufacturers - and their investors and underwriters - our Life Sciences practice is one of the largest in the world. We also work extensively with academic and medical institutions, hospitals and physicians, and other health care clients. Because our UK and US offices work seamlessly together, we have a unique ability to advise clients on their trans-Atlantic and international operations.

Our clients include emerging companies as well as established privately-held and publicly-listed companies. With practice strengths in areas such as intellectual property, company formation and governance, venture capital and financing, and deep industry experience in life sciences, health care, energy, clean technology and information technology, we serve as a springboard for many UK firms entering the US market and expanding internationally."

For more information visit:www.mintz.com